From time to time PCPC3’s members will come together to support and act towards specific short-term or long-term advocacy goals that may include a wide variety of issues — from approval of new forms of treatment to funding for specific initiatives or legislative action by Congress or individual states.

At this time, PCPC3 has an agreed set of long-term advocacy priorities that are supported by all of its members:

  • We continue to seek an appropriations increase to support the successful research activities of the Prostate Cancer Research Program within the Department of Defense’s Congressionally Directed Medical Research Program — from its current $80 million to $120 million per year (see this statement issued on April 25, 2016).
  • We join with the broader cancer community to support increased federal appropriations for cancer research for the National Institutes of Health, the National Cancer Institute, and the Centers for Disease Control and Prevention.
  • We support an increase to $400 million per year from the FY 2013 funding level of $255.6 million for basic and translational prostate cancer research at the National Cancer Institute.
  • We support legislative, research, and educational efforts needed to effectively combat — and ideally to eliminate — the epidemic of prostate cancer among African American men.
  • We support revisions to the decision-making processes of the U.S. Preventive Services Task Force (USPSTF) to ensure appropriate input from representatives of patient advocacy groups, specialty medical groups, and other federal agencies that have expertise in each area of preventive services under review.
  • We encourage the inclusion of quality-of-life-related endpoints, based on patient-reported outcomes data, in pivotal trials of all biologic and pharmaceutical agents being assessed for regulatory approval in the treatment of prostate cancer with a primary endpoint of improved survival — such that quality-of-life-related data (positive or negative) and survival data can be included in labeling for products indicated for the treatment of prostate cancer when appropriate.